Advances in Cancer Immunotherapy™: A Focus on Toxicity Management

When:  Apr 28, 2022 from 12:00 to 16:30 (CT)
This program will be hybrid. Please attend in-person or virtually!


Noha Abdel-Wahab, MD, PhD – The University of Texas MD Anderson Cancer Center
Adi Diab, MD – The University of Texas MD Anderson Cancer Center
Van Anh Trinh, PharmD – The University of Texas MD Anderson Cancer Cente

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

  • Describe the rationale for common approaches to cancer immunotherapy.
  • Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
  • Implement cancer immunotherapy treatments for skin cancers, lung, genitourinary, head and neck, hematologic cancers, and/or additional solid tumors into clinical practice appropriately.
  • Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

For more information on the program, click below.


View the SITC Meeting Code of Conduct.


Hilton Houston Plaza/Medical Center (in the Travis Ballroom)
6633 Travis Street
Houston, TX 77030